Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications. [PDF]
Wu YF, Chen JA, Jong YJ.
europepmc +1 more source
Predicting fragment binding modes using customized Lennard-Jones potentials in short molecular dynamics simulations. [PDF]
Vorreiter C, Robaa D, Sippl W.
europepmc +1 more source
Characterization of SMA type II skeletal muscle from treated patients shows OXPHOS deficiency and denervation. [PDF]
Grandi FC+8 more
europepmc +1 more source
Whole-transcriptome sequencing in neural and non-neural tissues of a mouse model identifies miR-34a as a key regulator in SMA pathogenesis. [PDF]
Wu L+9 more
europepmc +1 more source
Identification of coilin interactors reveals coordinated control of Cajal body number and structure. [PDF]
Arias Escayola D+8 more
europepmc +1 more source
Quantitative synthetic MRI reveals grey matter abnormalities in patients with spinal muscular atrophy types 2 and 3. [PDF]
Yan C+11 more
europepmc +1 more source
Role of senataxin in R-loop-mediated neurodegeneration. [PDF]
Kannan A+3 more
europepmc +1 more source
Dysregulation of innate immune signaling in animal models of spinal muscular atrophy. [PDF]
Garcia EL+5 more
europepmc +1 more source
SMN Deficiency Induces an Early Non-Atrophic Myopathy with Alterations in the Contractile and Excitatory Coupling Machinery of Skeletal Myofibers in the SMN∆7 Mouse Model of Spinal Muscular Atrophy. [PDF]
Berciano MT+8 more
europepmc +1 more source